Enanta Pharmaceuticals (ENTA) Shares Outstanding (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Shares Outstanding data on file, last reported at $29.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 35.95% year-over-year to $29.1 million; the trailing twelve-month figure through Mar 2026 stood at $29.1 million (up 35.95% YoY), and the FY2025 full-year result was $21.4 million, up 0.91% from the prior year.
• Shares Outstanding for Q1 2026 stood at $29.1 million, roughly flat from $29.0 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $29.1 million in Q1 2026 and bottomed at $20.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $21.2 million (2024), against an average of $22.0 million.
• The widest annual swing landed in 2024, when Shares Outstanding rose 0.6%; it then surged 36.03% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $20.9 million in 2022, then increased by 1.3% to $21.2 million in 2023, then climbed by 0.84% to $21.3 million in 2024, then soared by 36.03% to $29.0 million in 2025, then advanced by 0.14% to $29.1 million in 2026.
• The last three Shares Outstanding figures came in at $29.1 million (Q1 2026), $29.0 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.

Peer Comparison